FOSUN HEALTH Logo

Ovarian Cancer Prevention

catalogue

Ovarian Cancer Prevention

Ovarian Cancer Prevention

Ovarian cancer is the cancer where the honest statement is hardest: for women at average risk there is no screening test, and the disease is usually found late. Prevention therefore runs through genetics, surgery and ovulation biology — all of them real, none of them a general-population screening programme.

First: an honest risk picture

Prevention in ovarian cancer starts with knowing which risk tier you are in, because the tiers carry different actions. Average risk — no relevant family history — means symptom awareness and nothing else: no CA-125 screening, no annual ultrasound, both of which fail as screening tools. Family pattern — the configurations described on the causes page — means a genetics referral. Known carrier — a BRCA or other repair-gene variant — means a surveillance and surgery conversation with a genetics service.

What distinguishes this cancer from almost any other common one is how much of the prevention work is done by the family tree rather than by the individual: the hereditary fraction is large, and identifying it changes the options for relatives who have not yet been affected. A woman's first act of prevention, if there is a family pattern, is to have it assessed rather than watched.

Genetic testing: who and when

Testing is earned by the family configuration: ovarian cancer in a close relative at any age; breast cancer under roughly 45; male breast cancer; multiple breast/ovarian cancers on one side; Ashkenazi ancestry with either. For a woman diagnosed with epithelial ovarian cancer herself, testing is offered regardless of family history, on blood (germline) and tumour (BRCA, HRD) — because the result drives maintenance treatment as well as the family conversation.

The sequencing is worth knowing: the affected relative is tested first; a found variant makes each relative's test a simple yes-or-no; no variant found in the affected relative means the family is tested differently or reassured. Genetic counselling frames all of it — what a result does and does not mean, and what each outcome obliges or permits.

Risk-reducing surgery

The strongest available intervention is risk-reducing salpingo-oophorectomy — removal of ovaries and fallopian tubes, performed after childbearing is complete, timed by gene and family history (typically in the forties for BRCA2 and earlier for BRCA1, individualised with the genetics team). It reduces ovarian cancer risk dramatically and, performed at the recommended ages, contributes to reduced mortality in carriers.

Two facts make it workable. The fallopian tube discovery — most high-grade serous cancers begin there — is why removing tubes alone (opportunistic salpingectomy) at any other pelvic surgery already lowers risk without ending hormones. And the surgery's costs — immediate menopause for premenopausal women — are managed deliberately, with hormone therapy discussed case by case and bone and heart health planned for. It is a decision made with a genetics service, not against one.

Ovulation-aware choices

The ovulation–risk link gives average-risk women something real to work with. Oral contraceptives reduce ovarian cancer risk, the effect strengthening with years of use and persisting for decades — a genuine secondary benefit for any woman choosing contraception. Pregnancy and breastfeeding lower risk by suppressing ovulation, relevant as context rather than as prescription. Opportunistic salpingectomy — removing the tubes during a hysterectomy or tubal procedure done for other reasons — is now offered widely as a zero-extra-incision risk reduction.

None of these is a screening strategy, and none replaces the two things that matter most: knowing the family history, and taking the persistent-symptom cluster seriously when it appears. They tilt a lifetime risk; they do not set it to zero.

What prevention cannot do

The honest boundaries, stated plainly:

  • There is no screening test for average-risk women. CA-125 and ultrasound detect too few early cancers and raise too many false alarms; routine screening of average-risk women is not recommended anywhere.
  • Surveillance for carriers is imperfect. Ultrasound and CA-125 in known BRCA carriers detect disease late more often than early; this is why risk-reducing surgery, not surveillance, is the primary recommendation for carriers past childbearing.
  • Risk-reducing surgery changes life, not just risk. Surgical menopause has real consequences that need management; the decision is individualised, not automatic.

These limits are why the symptom cluster matters more here than in almost any other cancer: with no screening net, the persistent bloating–fullness–urgency pattern is the detection system that exists. The symptoms page sets out what earns an ultrasound.

A practical plan

For an individual woman, prevention reduces to four items with owners:

  • Map the family tree — cancers, ages, sides of the family; take it to a genetics service if any pattern from the causes page appears.
  • Test where the pattern warrants — and if a carrier, act on the surgery-and-surveillance conversation rather than postponing it.
  • Use the ovulation levers where they fit your life — contraceptive choices, opportunistic salpingectomy at any planned pelvic surgery.
  • Know the symptom cluster — and let persistence, not severity, trigger the ultrasound.

For patients of this hospital network, genetic counselling, testing and risk-reducing surgery are coordinated through the gynaecological oncology service, with reports and follow-up kept across borders.

Frequently Asked Questions

Should I have a CA-125 test every year just in case?

No, if you are at average risk without symptoms. As a screening test in healthy women, CA-125 finds too few early cancers and rises too often for benign reasons — routine testing produces operations and anxiety more than it prevents disease. The exceptions are structured: women with a known mass, patients on surveillance after treatment, and specific carrier-surveillance protocols agreed with a genetics service. For everyone else, the value is in the persistent symptom cluster, not in an annual number.

At what age should a BRCA carrier have risk-reducing surgery?

It is individualised, but the framework is clear: after childbearing is complete, and timed by gene — typically earlier for BRCA1 carriers and in the forties for BRCA2, based on when risk rises steeply. The decision balances the risk reduction against surgical menopause, and it is made with a genetics and gynaecology team, not from a table. What the framework does not support is indefinite postponement past the recommended window or surgery before the family plan is complete without full counselling.

Can the fallopian tubes be removed without removing the ovaries?

Yes — opportunistic salpingectomy, and it is one of the more useful recent ideas in this field. Because most high-grade serous cancers begin in the tube's fimbrial end, removing the tubes during a hysterectomy or other pelvic surgery lowers risk while leaving ovarian hormones intact. It is offered widely now at pelvic operations done for other reasons, particularly to women past their childbearing plans. It is risk reduction, not a guarantee, and it does not replace the genetics conversation.

I am a carrier and do not want surgery yet — what is my alternative?

Structured surveillance — pelvic ultrasound and CA-125 at defined intervals — is the alternative, and it is worth having with honest expectations: it detects recurrence of risk imperfectly and finds disease late more often than early. It is a bridge, not an equivalent, and the genetics team will keep the surgery conversation open as age and family plans evolve. Choosing surveillance is a legitimate decision; choosing it without knowing its limits is not.

Patient Stories

Stories from our ovarian cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Mapping your family history, or weighing surgery against surveillance?

Send the family pattern, any genetic results, and your questions. Our gynaecological and genetics team will reply in writing within 48 hours — with what to test, whom to test, and what each result would change.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*